{"transactions":[{"id":682790,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":91,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":548,"derivative":{"underlying":"Common Stock","underlying_shares":91},"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":682789,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":90,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":179,"derivative":{"underlying":"Common Stock","underlying_shares":90},"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":682788,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":64,"price":4.55,"value":291.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8679,"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":682787,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:33:11.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":true,"shares":181,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8743,"source":{"system":"sec-edgar","filing":"0001193125-26-355734","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355734/ownership.xml","form_type":"4"}},{"id":682786,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:27:35.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1993,"derivative":{"underlying":"Common Stock","underlying_shares":332},"source":{"system":"sec-edgar","filing":"0001193125-26-355722","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355722/ownership.xml","form_type":"4"}},{"id":682785,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:27:35.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":783,"derivative":{"underlying":"Common Stock","underlying_shares":390},"source":{"system":"sec-edgar","filing":"0001193125-26-355722","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355722/ownership.xml","form_type":"4"}},{"id":682784,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T21:27:35.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":263,"price":4.55,"value":1196.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":12499,"source":{"system":"sec-edgar","filing":"0001193125-26-355722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355722/ownership.xml","form_type":"4"}},{"id":682783,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T21:27:35.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":true,"shares":722,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":12762,"source":{"system":"sec-edgar","filing":"0001193125-26-355722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355722/ownership.xml","form_type":"4"}},{"id":682782,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:25:55.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":98,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":585,"derivative":{"underlying":"Common Stock","underlying_shares":98},"source":{"system":"sec-edgar","filing":"0001193125-26-355718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355718/ownership.xml","form_type":"4"}},{"id":682781,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:25:55.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":282,"derivative":{"underlying":"Common Stock","underlying_shares":140},"source":{"system":"sec-edgar","filing":"0001193125-26-355718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355718/ownership.xml","form_type":"4"}},{"id":682780,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:25:55.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":81,"price":4.55,"value":368.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7995,"source":{"system":"sec-edgar","filing":"0001193125-26-355718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355718/ownership.xml","form_type":"4"}},{"id":682779,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:25:55.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":true,"shares":238,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8076,"source":{"system":"sec-edgar","filing":"0001193125-26-355718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526355718/ownership.xml","form_type":"4"}},{"id":683336,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":667,"derivative":{"underlying":"Common Stock","underlying_shares":112},"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":683335,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":265,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":683334,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":82,"price":4.55,"value":373.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8117,"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":683333,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-18T21:22:57.000Z","date":"2026-08-15","kind":"exercise","planned":true,"acquired":true,"shares":245,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8199,"source":{"system":"sec-edgar","filing":"0001193125-26-355712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526355712/ownership.xml","form_type":"4"}},{"id":711024,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:12.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-300923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526300923/ownership.xml","form_type":"4"}},{"id":711025,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:11.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":7500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-300922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526300922/ownership.xml","form_type":"4"}},{"id":711023,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:06.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526300916/ownership.xml","form_type":"4"}},{"id":711022,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30935,"kind":"person","name":"Rosiello Robert L.","position":1,"cik":"0001645041","reported_name":"Rosiello Robert L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:05.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526300926/ownership.xml","form_type":"4"}},{"id":711136,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:02.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":7500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-300919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526300919/ownership.xml","form_type":"4"}},{"id":711021,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:02.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":18750,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001193125-26-300914","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526300914/ownership.xml","form_type":"4"}},{"id":711131,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:14.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000119312526300927/ownership.xml","form_type":"4"}},{"id":711073,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30952,"kind":"person","name":"Kender Richard N","position":1,"cik":"0001381205","reported_name":"Kender Richard N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:13.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date."}],"balance_after":50000,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-300925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381205/000119312526300925/ownership.xml","form_type":"4"}},{"id":711071,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30951,"kind":"person","name":"Fraser Claire","position":1,"cik":"0001382031","reported_name":"Fraser Claire","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:09.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382031/000119312526300921/ownership.xml","form_type":"4"}},{"id":711128,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:08.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000119312526300920/ownership.xml","form_type":"4"}},{"id":711072,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":16093,"kind":"person","name":"Ausiello Dennis A","position":1,"cik":"0001381994","reported_name":"Ausiello Dennis A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:07.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381994/000119312526300918/ownership.xml","form_type":"4"}},{"id":711205,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30998,"kind":"person","name":"Berenson Stephen","position":1,"cik":"0001760671","reported_name":"Berenson Stephen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:03.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760671/000119312526300924/ownership.xml","form_type":"4"}},{"id":718119,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30998,"kind":"person","name":"Berenson Stephen","position":1,"cik":"0001760671","reported_name":"Berenson Stephen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T22:12:53.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":7508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date."}],"balance_after":7508,"derivative":{"exercise_price":7.94,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":7508},"source":{"system":"sec-edgar","filing":"0001193125-26-295071","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1760671/000119312526295071/ownership.xml","form_type":"4"}},{"id":717189,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30935,"kind":"person","name":"Rosiello Robert L.","position":1,"cik":"0001645041","reported_name":"Rosiello Robert L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T22:09:52.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":7508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date."}],"balance_after":7508,"derivative":{"exercise_price":7.94,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":7508},"source":{"system":"sec-edgar","filing":"0001193125-26-295064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526295064/ownership.xml","form_type":"4"}},{"id":717401,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":16093,"kind":"person","name":"Ausiello Dennis A","position":1,"cik":"0001381994","reported_name":"Ausiello Dennis A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T22:05:59.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":7508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date."}],"balance_after":7508,"derivative":{"exercise_price":7.94,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":7508},"source":{"system":"sec-edgar","filing":"0001193125-26-295059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381994/000119312526295059/ownership.xml","form_type":"4"}},{"id":771804,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":779,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":771803,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":398,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":771802,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":79,"price":7.53,"value":594.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7954,"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":771801,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":true,"shares":244,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8033,"source":{"system":"sec-edgar","filing":"0001193125-26-230728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526230728/ownership.xml","form_type":"4"}},{"id":771235,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":2325,"derivative":{"underlying":"Common Stock","underlying_shares":331},"source":{"system":"sec-edgar","filing":"0001193125-26-230733","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230733/ownership.xml","form_type":"4"}},{"id":771234,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1173,"derivative":{"underlying":"Common Stock","underlying_shares":391},"source":{"system":"sec-edgar","filing":"0001193125-26-230733","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230733/ownership.xml","form_type":"4"}},{"id":771233,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":259,"price":7.53,"value":1950.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":12040,"source":{"system":"sec-edgar","filing":"0001193125-26-230733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230733/ownership.xml","form_type":"4"}},{"id":771232,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-19T20:05:04.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":true,"shares":722,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":12299,"source":{"system":"sec-edgar","filing":"0001193125-26-230733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230733/ownership.xml","form_type":"4"}},{"id":771239,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":false,"shares":91,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":639,"derivative":{"underlying":"Common Stock","underlying_shares":91},"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":771238,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":false,"shares":89,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":269,"derivative":{"underlying":"Common Stock","underlying_shares":89},"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":771237,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-18","kind":"sale","planned":false,"acquired":false,"shares":59,"price":7.53,"value":444.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares sold to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8562,"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":771236,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":true,"shares":180,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8621,"source":{"system":"sec-edgar","filing":"0001193125-26-230732","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230732/ownership.xml","form_type":"4"}},{"id":771231,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":97,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":683,"derivative":{"underlying":"Common Stock","underlying_shares":97},"source":{"system":"sec-edgar","filing":"0001193125-26-230727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230727/ownership.xml","form_type":"4"}},{"id":771230,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":422,"derivative":{"underlying":"Common Stock","underlying_shares":141},"source":{"system":"sec-edgar","filing":"0001193125-26-230727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230727/ownership.xml","form_type":"4"}},{"id":771229,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":77,"price":7.53,"value":579.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7838,"source":{"system":"sec-edgar","filing":"0001193125-26-230727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230727/ownership.xml","form_type":"4"}},{"id":771228,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-19T20:05:03.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":true,"shares":238,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7915,"source":{"system":"sec-edgar","filing":"0001193125-26-230727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526230727/ownership.xml","form_type":"4"}},{"id":848195,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22048,"kind":"person","name":"Brady Kelly","position":1,"cik":"0002117686","reported_name":"Brady Kelly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-11T22:39:08.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":56250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":56250,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":56250},"source":{"system":"sec-edgar","filing":"0001193125-26-102617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526102617/ownership.xml","form_type":"4"}},{"id":855450,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:35:04.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":75000,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193125-26-096700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526096700/ownership.xml","form_type":"4"}},{"id":855448,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:33:50.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":22500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001193125-26-096692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526096692/ownership.xml","form_type":"4"}},{"id":855781,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:31:52.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":22500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001193125-26-096678","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526096678/ownership.xml","form_type":"4"}},{"id":855585,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30952,"kind":"person","name":"Kender Richard N","position":1,"cik":"0001381205","reported_name":"Kender Richard N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T16:36:52.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and become exercisable in 36 equal monthly installments."}],"balance_after":150000,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-26-096711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381205/000119312526096711/ownership.xml","form_type":"4"}},{"id":895805,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:14.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":2656,"derivative":{"underlying":"Common Stock","underlying_shares":333},"source":{"system":"sec-edgar","filing":"0001193125-26-057156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057156/ownership.xml","form_type":"4"}},{"id":895804,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:14.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1564,"derivative":{"underlying":"Common Stock","underlying_shares":391},"source":{"system":"sec-edgar","filing":"0001193125-26-057156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057156/ownership.xml","form_type":"4"}},{"id":895803,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T21:30:14.000Z","date":"2026-02-15","kind":"sale","planned":true,"acquired":false,"shares":259,"price":8.47,"value":2193.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":11577,"source":{"system":"sec-edgar","filing":"0001193125-26-057156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057156/ownership.xml","form_type":"4"}},{"id":895802,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T21:30:14.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":true,"shares":723,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":11836,"source":{"system":"sec-edgar","filing":"0001193125-26-057156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057156/ownership.xml","form_type":"4"}},{"id":895801,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:10.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":98,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":780,"derivative":{"underlying":"Common Stock","underlying_shares":98},"source":{"system":"sec-edgar","filing":"0001193125-26-057157","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057157/ownership.xml","form_type":"4"}},{"id":895800,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:10.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":531,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-26-057157","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057157/ownership.xml","form_type":"4"}},{"id":895799,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:10.000Z","date":"2026-02-15","kind":"sale","planned":true,"acquired":false,"shares":75,"price":8.47,"value":635.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8557,"source":{"system":"sec-edgar","filing":"0001193125-26-057157","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057157/ownership.xml","form_type":"4"}},{"id":895798,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:10.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":true,"shares":231,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8632,"source":{"system":"sec-edgar","filing":"0001193125-26-057157","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057157/ownership.xml","form_type":"4"}},{"id":896592,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":890,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":896591,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":531,"derivative":{"underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":896590,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"sale","planned":true,"acquired":false,"shares":78,"price":8.47,"value":660.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7789,"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":896589,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:06.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":true,"shares":244,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7867,"source":{"system":"sec-edgar","filing":"0001193125-26-057154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312526057154/ownership.xml","form_type":"4"}},{"id":895797,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:05.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":98,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":780,"derivative":{"underlying":"Common Stock","underlying_shares":98},"source":{"system":"sec-edgar","filing":"0001193125-26-057153","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057153/ownership.xml","form_type":"4"}},{"id":895796,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2026-02-18T21:30:05.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":false,"shares":141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":563,"derivative":{"underlying":"Common Stock","underlying_shares":141},"source":{"system":"sec-edgar","filing":"0001193125-26-057153","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057153/ownership.xml","form_type":"4"}},{"id":895795,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:05.000Z","date":"2026-02-15","kind":"sale","planned":true,"acquired":false,"shares":89,"price":8.47,"value":753.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7677,"source":{"system":"sec-edgar","filing":"0001193125-26-057153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057153/ownership.xml","form_type":"4"}},{"id":895794,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-18T21:30:05.000Z","date":"2026-02-15","kind":"exercise","planned":true,"acquired":true,"shares":239,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7766,"source":{"system":"sec-edgar","filing":"0001193125-26-057153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526057153/ownership.xml","form_type":"4"}},{"id":995176,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:27.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":98,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":878,"derivative":{"underlying":"Common Stock","underlying_shares":98},"source":{"system":"sec-edgar","filing":"0001193125-25-286236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286236/ownership.xml","form_type":"4"}},{"id":995175,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:27.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":664,"derivative":{"underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001193125-25-286236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286236/ownership.xml","form_type":"4"}},{"id":995174,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:27.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":3998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3998},"source":{"system":"sec-edgar","filing":"0001193125-25-286236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286236/ownership.xml","form_type":"4"}},{"id":995173,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:27.000Z","date":"2025-11-15","kind":"sale","planned":true,"acquired":false,"shares":1042,"price":17.3,"value":18026.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 5, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":8401,"source":{"system":"sec-edgar","filing":"0001193125-25-286236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286236/ownership.xml","form_type":"4"}},{"id":995172,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:27.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":9443,"source":{"system":"sec-edgar","filing":"0001193125-25-286236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286236/ownership.xml","form_type":"4"}},{"id":995171,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:27.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":132,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":9345,"source":{"system":"sec-edgar","filing":"0001193125-25-286236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286236/ownership.xml","form_type":"4"}},{"id":995170,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:27.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":3998,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":9213,"source":{"system":"sec-edgar","filing":"0001193125-25-286236","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286236/ownership.xml","form_type":"4"}},{"id":995169,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:25.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":2989,"derivative":{"underlying":"Common Stock","underlying_shares":331},"source":{"system":"sec-edgar","filing":"0001193125-25-286235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286235/ownership.xml","form_type":"4"}},{"id":995168,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:25.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1954,"derivative":{"underlying":"Common Stock","underlying_shares":390},"source":{"system":"sec-edgar","filing":"0001193125-25-286235","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286235/ownership.xml","form_type":"4"}},{"id":995167,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T21:30:25.000Z","date":"2025-11-15","kind":"sale","planned":true,"acquired":false,"shares":217,"price":17.3,"value":3754.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":11113,"source":{"system":"sec-edgar","filing":"0001193125-25-286235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286235/ownership.xml","form_type":"4"}},{"id":995166,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T21:30:25.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":331,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":11330,"source":{"system":"sec-edgar","filing":"0001193125-25-286235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286235/ownership.xml","form_type":"4"}},{"id":995165,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T21:30:25.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":390,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":10999,"source":{"system":"sec-edgar","filing":"0001193125-25-286235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286235/ownership.xml","form_type":"4"}},{"id":995559,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1001,"derivative":{"underlying":"Common Stock","underlying_shares":112},"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995558,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":664,"derivative":{"underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995557,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"sale","planned":true,"acquired":false,"shares":76,"price":17.3,"value":1314.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7623,"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995556,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7699,"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995555,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:23.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":132,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7587,"source":{"system":"sec-edgar","filing":"0001193125-25-286240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525286240/ownership.xml","form_type":"4"}},{"id":995164,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:04.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":98,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":878,"derivative":{"underlying":"Common Stock","underlying_shares":98},"source":{"system":"sec-edgar","filing":"0001193125-25-286226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286226/ownership.xml","form_type":"4"}},{"id":995163,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:04.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":704,"derivative":{"underlying":"Common Stock","underlying_shares":140},"source":{"system":"sec-edgar","filing":"0001193125-25-286226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286226/ownership.xml","form_type":"4"}},{"id":995162,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-11-18T21:30:04.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":false,"shares":3998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested in a single installment on November 15, 2025. The RSUs have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3998},"source":{"system":"sec-edgar","filing":"0001193125-25-286226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286226/ownership.xml","form_type":"4"}},{"id":995161,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:04.000Z","date":"2025-11-15","kind":"sale","planned":true,"acquired":false,"shares":1257,"price":17.3,"value":21746.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":7527,"source":{"system":"sec-edgar","filing":"0001193125-25-286226","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286226/ownership.xml","form_type":"4"}},{"id":995160,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:04.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8784,"source":{"system":"sec-edgar","filing":"0001193125-25-286226","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286226/ownership.xml","form_type":"4"}},{"id":995159,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:04.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":140,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8686,"source":{"system":"sec-edgar","filing":"0001193125-25-286226","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286226/ownership.xml","form_type":"4"}},{"id":995158,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-18T21:30:04.000Z","date":"2025-11-15","kind":"exercise","planned":true,"acquired":true,"shares":3998,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8546,"source":{"system":"sec-edgar","filing":"0001193125-25-286226","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525286226/ownership.xml","form_type":"4"}},{"id":1030362,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":65846,"kind":"person","name":"Young Teresa L.","position":1,"cik":"0001814656","reported_name":"Young Teresa L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-09-30T20:30:06.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":3998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date."}],"balance_after":3998,"derivative":{"underlying":"Common Stock","underlying_shares":3998},"source":{"system":"sec-edgar","filing":"0001193125-25-225105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525225105/ownership.xml","form_type":"4"}},{"id":1030361,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22046,"kind":"person","name":"Henn Matthew R","position":1,"cik":"0001767321","reported_name":"Henn Matthew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-09-30T20:30:03.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":3998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in a single installment on November 15, 2025, subject to the Reporting Person's satisfaction of the terms contemplated in the award agreement.The RSUs have no expiration date."}],"balance_after":3998,"derivative":{"underlying":"Common Stock","underlying_shares":3998},"source":{"system":"sec-edgar","filing":"0001193125-25-225103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525225103/ownership.xml","form_type":"4"}},{"id":1061222,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-08-19T20:08:56.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":3320,"derivative":{"underlying":"Common Stock","underlying_shares":333},"source":{"system":"sec-edgar","filing":"0000950170-25-110096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017025110096/ownership.xml","form_type":"4"}},{"id":1061221,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-08-19T20:08:56.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":2344,"derivative":{"underlying":"Common Stock","underlying_shares":391},"source":{"system":"sec-edgar","filing":"0000950170-25-110096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017025110096/ownership.xml","form_type":"4"}},{"id":1061220,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T20:08:56.000Z","date":"2025-08-18","kind":"sale","planned":true,"acquired":false,"shares":217,"price":16.65,"value":3613.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."}],"balance_after":10609,"source":{"system":"sec-edgar","filing":"0000950170-25-110096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017025110096/ownership.xml","form_type":"4"}},{"id":1061219,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T20:08:56.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":true,"shares":333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":10826,"source":{"system":"sec-edgar","filing":"0000950170-25-110096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017025110096/ownership.xml","form_type":"4"}},{"id":1061218,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22047,"kind":"person","name":"Shaff Eric D.","position":1,"cik":"0001643734","reported_name":"Shaff Eric D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-19T20:08:56.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":true,"shares":391,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":10493,"source":{"system":"sec-edgar","filing":"0000950170-25-110096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017025110096/ownership.xml","form_type":"4"}},{"id":1061725,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":22183,"kind":"person","name":"DesRosier Thomas","position":1,"cik":"0001435744","reported_name":"DesRosier Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-08-19T20:07:47.000Z","date":"2025-08-15","kind":"exercise","planned":true,"acquired":false,"shares":111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":1113,"derivative":{"underlying":"Common Stock","underlying_shares":111},"source":{"system":"sec-edgar","filing":"0001193125-25-183436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1435744/000119312525183436/ownership.xml","form_type":"4"}}],"next_cursor":"2025-08-19T20:07:47.000000Z,1061725"}